The FDA is currently reviewing Medtronic's submission for its MiniMed 780G system, specifically regarding its use for Type 2 diabetes and label expansion into Europe.
2 reports, 2 independent
Updated Jul 24
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA is currently reviewing Medtronic's submission for its MiniMed 780G system, specifically regarding its use for Type 2 diabetes and label expansion into Europe.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Congress considered proposals to strengthen FDA authority regarding medical device regulation and minimum standards.
- OS Therapies, Inc. is seeking interim and final review data submissions from regulatory bodies while attending major global investment conferences.
- MDR/IVDR reforms require adoption by the European Parliament, referencing US FDA pre-submission meetings.
- The FDA operates under US law to evaluate international clinical data.
- Future sales of a product are contingent upon obtaining the necessary FDA registration and labeling, while the state simultaneously announces actions to remove regulatory barriers.
Coverage
Newest first; wire copies grouped- MedTech DiveMedtronic receives Type 2 label expansion for MiniMed 780G in Europe This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive
- Medical Device NetworkMedtronic’s MiniMed 780G system gains CE Mark for expanded indications Medtronic’s MiniMed 780G system has received European CE Mark approval to expand the indications for use by people aged two year